Skip to main content
Premium Trial:

Request an Annual Quote

Pluvita Subscribes to AxCell s Proteomics Database

NEW YORK, Nov. 28 – Biotechnology company Pluvita has signed a three-year, non-exclusive deal for access to AxCell Bioscience’s ProChart database, which contains information on signal transduction pathways in the human proteome, AxCell said Wednesday.

Financial terms of the deal were not disclosed.

The database includes the map of the WW protein domain family, a complete human domain family involved in signal transduction. ProChart also includes protein pathway information from several other domain families, such as PDZ, SH2 and SH3.

"AxCell Biosciences' ProChart database represents a critical addition to Pluvita's drug discovery efforts by enabling us to expand our unique approach to target and lead identification and optimization," Gary Kurtzman, CEO of Pluvita, said in a statement.

Pluvita of Bethesda, Md., said it would use the database in a number of its research and drug discovery initiatives, in areas such as cancer, reproductive health, and diabetes. 

ProChart was launched in June as part of Informax’s GenoMax bioinformatics system. 

AxCell Biosciences of Princeton, NJ, is a subsidiary of Cytogen.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.